The FDA on 21 June 2013 expanded the approved use of the antibiotic Vibativ (telavancin) from Theravance, to treat patients...
Theravance Biopharma, Inc. announced the sale of its proprietary antibiotic, Vibativ (telavancin), to Cumberland Pharmaceuticals, Inc. a specialty pharmaceutical company...
The Advisory Committee (AIDAC) of the FDA has voted 9-6 that data, from Theravance relative to Vibativ (telavancin), failed to...
Theravance Biopharma announced that positive new data from multiple studies of Vibativ (telavancin) in treating infection from the ongoing Telavancin...
Astellas and Theravance have received marketing authorisation from the European Commission for Vibativ (telavancin hydrochloride) for nosocomial pneumonia caused by...
Theravance Biopharma, Inc. announced new positive data from several studies of Vibativ (telavancin) confirming the product's in vitro potency against...
Cumberland Pharmaceuticals has announced a new publication in Infectious Diseases and Therapy, showing numerically superior cure rates of Vibativ (telavancin)...
Theravance Biopharma, Inc.announced that positive new data from multiple studies of Vibativ (telavancin) were presented at the 28th European Congress...
Clinigen Group plc announced that the European Commission (EC) has ratified the positive opinion in January 2014 from the European...